Brimonidine tartrate for the treatment of glaucoma

References

• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090.
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713.
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, et al. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999;106(11):2144–2153.
   PubMed Web of Science ®Google Scholar
• Ederer F, Gaasterland DE, Sullivan EK. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials. 1994;15(4):299–325.
   PubMedGoogle Scholar
• Stähle H. A historical perspective: development of clonidine. Best Pract Res Clin Anaesthesiology. 2000;14(2):237–246.
   Google Scholar
• Hodapp E, Kolker A, Kass M, et al. The effect of topical clonidine on intraocular pressure. Arch Ophthalmol. 1981;99:1208–1211.
   PubMed Web of Science ®Google Scholar
• Harrison R, Kaufmann CS. Clonidine. Effects of a topically administered solution on intraocular pressure and blood pressure in open-angle glaucoma. Arch Ophthalmol. 1977;95(8):1368–1373.
   PubMedGoogle Scholar
• Bill A, Heilmann K. Ocular effects of clonidine in cats and monkeys (Macaca irus). Exp Eye Res. 1975;21(5):481–488.
   PubMed Web of Science ®Google Scholar
• Petursson G, Cole R, Hanna C. Treatment of glaucoma using minidrops of clonidine. Arch Ophthalmol. 1984;102(8):1180–1181.
   PubMedGoogle Scholar
• Sebastiani A, Parmeggiani F, Costagliola C, et al. Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma. Acta Ophthalmol Scand Suppl. 2002;236:29–30.
   PubMedGoogle Scholar
• Costagliola C, Parmeggiani F, Ciancaglini M, et al. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. Ophthalmologica. 2003;217(1):39–44.
   PubMed Web of Science ®Google Scholar
• Cardakli F, Smythe B, Eisele J, et al. Effect of chronic apraclonidine treatment on intraocular pressure in advanced glaucoma. J. Glaucoma. 1992;1:271–278.
   PubMedGoogle Scholar
• Thompson CD, Macdonald TL, Garst ME, et al. Mechanisms of adrenergic agonist induced allergy: bioactivation and antigen formation. Exp Eye Res. 1997;64(5):767–773.
   PubMed Web of Science ®Google Scholar
• Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000;1(4):815–34.17. Rasmussen CA, Kaufman PL, and Kiland JA. Benzalkonium chloride and glaucoma. J Ocul Pharmacol Ther 2014; 30 (2–3): 163–9.
   PubMedGoogle Scholar
• Datta S, Baudouin C, Brignole-Baudouin F, et al. The eye drop preservative benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells. Invest Ophthalmol Vis Sci. 2017;58(4):2406–2412.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312–334.
   PubMed Web of Science ®Google Scholar
• Mirza SK, Johnson SM. Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2010;4:877–888.
   PubMedGoogle Scholar
• Dong JQ, Babusis DM, Welty DF, et al. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther. 2004;20(4):285–292.
   PubMed Web of Science ®Google Scholar
• “NDA 2013/S-031.” [cited 2018 Jun 01]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2016/020613s031lbl.pdf
   Google Scholar
• Cantor LB, Wudunn D, Catoira-Boyle Y, et al. Absorption of brimonidine 0.1% and 0.15% ophthalmic solutions in the aqueous humor of cataract patients. J Glaucoma. 2008;17(7):529–534.
   PubMed Web of Science ®Google Scholar
• Nguyen QH. Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence. 2014;8:853–864.
   PubMed Web of Science ®Google Scholar
• Lo JS, Pang PM, Lo SC. Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs. Clin Ophthalmol. 2016;10:583–586.
   PubMed Web of Science ®Google Scholar
• Sun J, Lei Y, Dai Z, et al. Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma. ACS Appl Mater Interfaces. 2017;9(9):7990–7999.
   PubMed Web of Science ®Google Scholar
• Chiang B, Kim YC, Doty AC, et al. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma. J Control Release. 2016;228:48–57.
   PubMed Web of Science ®Google Scholar
• Cambridge D. UK-14,304, a potent and selective alpha-2-agonist for the characterization of alphaadrenoceptor subtype. Eur J Pharmacol. 1981;72:413–415.
   PubMed Web of Science ®Google Scholar
• Gilsbach R, Hein L. Are the pharmacology and physiology of α₂ drenoceptors determined by α₂-heteroreceptors and autoreceptors respectively? Br J Pharmacol. 2012;165(1):90–102.
   PubMed Web of Science ®Google Scholar
• Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514–1517.
   PubMed Web of Science ®Google Scholar
• Adkins JC, Balfour JA. Brimonidine: a review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging. 1998;12:225–241.
   PubMed Web of Science ®Google Scholar
• Tripathi RC, Yang C, Tripathi BJ, et al. Role of receptors in the trabecular meshwork of the eye as targeted to the development of antiglaucoma therapy. Drug Dev Res. 1992;27:191–228.
   Web of Science ®Google Scholar
• Stamer WD, Huang Y, Seftor RE, et al. Cultured human trabecular meshwork cells express functional alpha 2A adrenergic receptors. Iovs. 1996;37:2426–2433.
   PubMed Web of Science ®Google Scholar
• Castagliola C, Dell’omo R, Romano MR, et al. Pharmacotherapy of intraocular pressure: part 1. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin Pharmacother. 2009;10:2663–2677.
   PubMed Web of Science ®Google Scholar
• Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res. 2011;93:271–283.
   PubMed Web of Science ®Google Scholar
• Kesler A, Shemesh G, Rothkoff L, et al. Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size. J Cataract Refract Surg. 2004;30(8):1707–1710.
   PubMed Web of Science ®Google Scholar
• Niyadurupola N, Broadway DC. Pigment dispersion syndrome and pigmentary glaucoma–a major review. Clin Experiment Ophthalmol. 2008;36:868–882.
   PubMed Web of Science ®Google Scholar
• Besada E, Reed K, Najman P, et al. Pupillometry study of brimonidine tartrate 0.2% and apraclonidine 0.5%. J Clin Pharmacol. 2011;51(12):1690–1695.
   PubMed Web of Science ®Google Scholar
• Shemesh G, Mojssejev E, Lazar M, et al. Effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter. J Cataract Refract Surg. 2011;37(3):486–489.
   PubMed Web of Science ®Google Scholar
• Gerente VM, Biondi AC, Barbosa CP, et al. Effect of brimonidine tartrate 0.15% on scotopic pupil: controlled trial. J Ocul Pharmacol Ther. 2007;23(5):476–480.
   PubMed Web of Science ®Google Scholar
• Scheie HG, Cameron JD. Pigment dispersion syndrome: a clinical study. Br J Ophthalmol. 1981;65:264–269.
   PubMed Web of Science ®Google Scholar
• Acheampong AA, Shackleton M, Tang-Liu DD. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos. 1995;23(7):708–712.
   PubMed Web of Science ®Google Scholar
• Blondeau P, Rousseau JA. Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol. 2002;37(1):21–26.
   PubMed Web of Science ®Google Scholar
• Beltz J, Zamir E. Brimonidine induced anterior uveitis. Ocul Immunol Inflamm. 2016;24(2):128–133.
   PubMed Web of Science ®Google Scholar
• Sullivan-Mee M, Pensyl D, Alldredge B, et al. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations. J Ocul Pharmacol Ther. 2010;26(4):355–360.
   PubMed Web of Science ®Google Scholar
• Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine study groups 1 and 2. Ophthalmology. 2000;107:1171–1177.
   PubMed Web of Science ®Google Scholar
• Carlsen JO, Zabriskie NA, Kwon YH, et al. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol. 1999;128:255e256.
   Web of Science ®Google Scholar
• Daubert GP. Is brimonidine ophthalmic a safe therapy for infants? J Clin Pharm Ther. 2006;31:289e292.
   Web of Science ®Google Scholar
• Al-Shahwan S, Al-Torbak AA, Turkmani S, et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology. 2005;112(12):2143.e1–2143.e7.
   PubMed Web of Science ®Google Scholar
• Sethi HS, Naik M, Gupta VS. Management of glaucoma in pregnancy: risks or choices, a dilemma? Int J Ophthalmol. 2016;9(11):1684–1690.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol. 2001;131(6):798–799.
   PubMed Web of Science ®Google Scholar
• Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41(Suppl 1):S9–18.
   PubMed Web of Science ®Google Scholar
• Burke JA, Potter DE. Ocular effects of a relatively selective alpha 2 agonist (UK-14, 304-18) in cats, rabbits and monkeys. Curr Eye Res. 1986;5(9):665–676.
   PubMed Web of Science ®Google Scholar
• Serle JB, Steidl S, Wang RF, et al. Selective alpha 2-adrenergic agonists B-HT 920 and UK14304-18. Effects on aqueous humor dynamics in monkeys. Arch Ophthalmol. 1991;109(8):1158–1162.
   PubMedGoogle Scholar
• Burke J, Kharlamb A, Shan T, et al. Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys. A species difference. Ann N Y Acad Sci. 1995;763:78–95.
   PubMedGoogle Scholar
• Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996;41(Suppl 1):S19–26.
   PubMed Web of Science ®Google Scholar
• Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11(2):119–126.
   PubMed Web of Science ®Google Scholar
• Mundorf T, Williams R, Whitcup S, et al. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003;19(1):37–44.
   PubMed Web of Science ®Google Scholar
• Cantor LB, Safyan E, Liu CC, et al. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Curr Med Res Opin. 2008;24(7):2035–2043.
   PubMed Web of Science ®Google Scholar
• Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011;151(4):671–681.
   PubMed Web of Science ®Google Scholar
• Gandolfi SA, Cimino L, Mora P. Effect of brimonidine on intraocular pressure in normal tension glaucoma: a short term clinical trial. Eur J Ophthalmol. 2003;13(7):611–615.
   PubMed Web of Science ®Google Scholar
• Liu CJ, Ko YC, Cheng CY, et al. Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma. Br J Ophthalmol. 2002;86(11):1236–1239.
   PubMed Web of Science ®Google Scholar
• Sharpe ED, Day DG, Beischel CJ, et al. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2004;88(7):953–956.
   PubMed Web of Science ®Google Scholar
• Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine study group. Am J Ophthalmol. 1999;127(1):20–26.
   PubMed Web of Science ®Google Scholar
• Dubiner HB, Mroz M, Shapiro AM, et al. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther. 2001;23(12):1969–1983.
   PubMed Web of Science ®Google Scholar
• Kampik A, Arias-Puente A, O’brart DP, et al. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma. 2002;11(2):90–96.
   PubMed Web of Science ®Google Scholar
• Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology. 2009;116(9):1719–1724.
   PubMed Web of Science ®Google Scholar
• Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2008 May;24(5):1435–1442.
   PubMed Web of Science ®Google Scholar
• Feldman RM, Tanna AP, Gross RL, et al. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology. 2007;114(7):1248–1254.
   PubMed Web of Science ®Google Scholar
• Reis R, Queiroz CF, Santos LC, et al. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clinical Therapeutics. 2006;28(4):552–559.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Katsanos A, Quaranta L, et al. Twenty-four hour efficacy of glaucoma medications. Prog Brain Res. 2015;221:297–318.
   PubMed Web of Science ®Google Scholar
• Liu JHK, Medeiros FA, Slight R, et al. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology. 2010;117(11):2075–2079.
   PubMed Web of Science ®Google Scholar
• Linsell CR, Lightman SL, Mullen PE, et al. Circadian rhythms of epinephrine and norepinephrine in man. J Clin Endocrinol Metab. 1985;60(6):1210–1215.
   PubMed Web of Science ®Google Scholar
• WoldeMussie E, Ruiz G, Wijono M, et al. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:2849–2855.
   PubMed Web of Science ®Google Scholar
• Nizari S, Guo L, Davis BM, et al. Non-amyloidogenic effects of α2 adrenergic agonists: implications for brimonidine-mediated neuroprotection. Cell Death Dis. 2016;7(12):e2514.
   PubMedGoogle Scholar
• Semba K, Namekata K, Kimura A, et al. Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma. Cell Death Dis. 2014;5:e1341.
   PubMed Web of Science ®Google Scholar
• Rahman MQ, Ramaesh K, Montgomery DM. Brimonidine for glaucoma. Expert Opin Drug Saf. 2010;9(3):483–491.
   PubMed Web of Science ®Google Scholar
• Feke GT, Bex PJ, Taylor CP, et al. Effect of brimonidine on retinal vascular autoregulation and short-term visual function in normal tension glaucoma. Am J Ophthalmol. 2014 Jul;158(1):105–112.
   PubMed Web of Science ®Google Scholar
• De Moraes CG, Liebmann JM, Greenfield DS, et al. Low-pressure glaucoma treatment study group. Risk factors for visual field progression in the low-pressure glaucoma treatment study. Am J Ophthalmol. 2012 Oct;154(4):702–711.
   PubMed Web of Science ®Google Scholar
• Krupin T, Liebmann JM, Greenfield DS, et al. Low-pressure glaucoma study group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011 Apr;151(4):671–681.
   PubMed Web of Science ®Google Scholar
• Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2017 Jan 25;1:CD006539. doi: 10.1002/14651858.CD006539.pub4.
   PubMed Web of Science ®Google Scholar
• “α 2-Adrenergic Agonists.” American Academy of Ophthalmology, [cited 2018 Jun 01]. Available from: www.aao.org/bcscsnippetdetail.aspx?id=8bbe8f08-17b9-48fc-ae5d-1bc7a0c18b4d.
   Google Scholar
• European glaucoma society terminology and guidelines for glaucoma, 4th Edition - Chapter 3: treatment principles and options. Supported by the EGS Foundation Br J Ophthalmol. 2017; 101:130–195.
   PubMed Web of Science ®Google Scholar